Iron AbsorptionNCT03894358
Iron Absorption From a Wheat-based Instant Cereal:Gut and Stable Isotope Studies in Kenyan Infants
A study testing FeFum and 7.5 g prebiotic mixture, FeFum and 3 g prebiotic mixture and Fefum and no prebiotic mixture in people with Iron Absorption and Gut Microbiota, run by Swiss Federal Institute of Technology at 1 site in Kenya.
Trial summary
The aim of this study is to measure the effect of a prebiotic (high dose/low dose) mixture at different doses within a wheat-based instant cereal, on fractional iron absorption (FIA), gut microbiota and inflammation after three weeks. Read more about this study
- Who is it for?
- Ages 6 to 11 monthsHealthy volunteers can take part
- Conditions the study is for
- Iron Absorption, Gut Microbiota
- What is being tested?
- FeFum and 7.5 g prebiotic mixture, FeFum and 3 g prebiotic mixture and Fefum and no prebiotic mixture
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 195 participants
- Where
- 1 siteKenya
- Study dates
- 23 Jul 2019to 4 Jan 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 11 months
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- 6 to 11 months at baseline
- Anticipated residence in study area for the study duration
- In good health as assessed by professional staff at Msambweni County Referral hospital
- Caregiver is willing to participate and able to comply with study procedures
- Informed consent form has been read and signed by the caregiver (or has been read out to the caregiver)
Who cannot join
- Hemoglobin concentration less than 70 g/L
- Severe underweight (Z-score weight-for-age <-3)
- Severe wasting (Z-score weight-for-height <-3
- Chronic or acute illness or other conditions that in the opinion of the Principal Investigator (PI) or study pediatrician would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol
- Participant taking part in other studies requiring the drawing of blood
- Regular intake (>2 days) of iron-containing mineral and vitamin supplements or fortified foods within the last 2 months
- Antibiotic treatment in the past 4 weeks prior to study enrollment
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Iron Absorption From a Wheat-based Instant Cereal Containing Ferrous Fumarate and Ascorbic Acid With and Without Prebiotics: Gut Microbiome and Stable Isotope Studies in Kenyan Infants
The aim of this study is to measure the effect of a prebiotic (high dose/low dose) mixture at different doses within a wheat-based instant cereal, on fractional iron absorption (FIA), gut microbiota and inflammation after three weeks. FIA will be compared with and without three weeks of pre-feeding with two different doses of the prebiotic mixture.
Read the detailed description
Iron deficiency anemia (IDA) is prevalent in infants and preschool children in sub-Saharan Africa. Several studies have been conducted to mitigate IDA. Some of these studies had adverse effects on the gut microbiome and diarrhea due to the high iron dose administered in areas of high burden of malaria and other common childhood infections. As a potentially safer solution, we investigated the effect of lowering the iron dose in the iron supplements and including 7.5 g galacto-oligosaccharides (GOS). Findings from these studies demonstrated that in infants, consumption of iron and GOS improved iron status, improved the gut microbiota and reduced risk of illness. We recently demonstrated that habitual consumption of GOS for three weeks resulted in improved iron absorption that correlated with a decrease in colonic pH. It is not known whether other prebiotics or a combination will also result in increased iron absorption and what the effect of using half the dose of prebiotics would be. The composition of Human Milk Oligosaccharides (HMOs) in breast milk might be an important determinant of the gut microbiome composition and health of the breastfed infant by determining the composition of Bifidobacteria species that are the main commensal 'barrier' bacteria in the infant's gut microbiome. However, little is known about the specific HMOs composition of breast milk in African populations and the potential impact on the gut microbiota composition of the breastfed infants. We therefore aim to measure the effect of a prebiotic (high dose/low dose) mixture at different doses within a wheat-based instant cereal, on fractional iron absorption (FIA) from a wheat-based instant cereal containing no prebiotic. We will compare the FIA with and without three weeks of pre-feeding with two different doses of prebiotic mixture. In addition, we will investigate the effect of two different doses of this prebiotic (high dose/low dose) mixture on gut microbiota and inflammation after three weeks.
In south coast Kenya, we will enroll 195 infants and randomize them into three intervention groups. Daily for 3 weeks, infants will consume a newly formulated wheat-based instant cereal (3.6 mg iron with Ascorbic acid (AA)) at home. Group 1 will receive the cereal with 7.5 g prebiotic mixture; group 2 will receive the cereal with 3 g prebiotic mixture and group 3 will receive the cereal with no prebiotics. In a subset of 70 infants, we will administer four labelled test meals. Two test meals will be fed 2 weeks before beginning the intervention study to investigate the acute effect of prebiotics on FIA and the other two will be fed at the end of the 3 weeks intervention study to investigate the effect of chronic consumption of prebiotics on FIA. Breast milk samples from the mothers will be collected and analyzed for the composition of human milk oligosaccharides (HMOs). We hypothesize that: 1) Infants receiving the new wheat-based instant cereal containing prebiotic (high dose/low dose) mixture will have a higher iron absorption, and 2) higher fecal Bifidobacteria abundance than infants receiving the cereal without prebiotics; 3) in infants receiving the wheat-based instant cereal, the addition of 7.5 g of prebiotic (high dose/low dose) mixture will result in higher FIA, and 4) in greater ratio of Bifidobacteria to Enterobacteriaceae, lowest fecal calprotectin, intestinal fatty acid-binding protein (I-FABP) and lowest abundances of enteropathogens than the addition of 3 g of prebiotics; 5) the addition of 7.5 g of prebiotic (high dose/low dose) mixture will result in greater FIA when administered acutely or chronically and these two effects will be additive; 6) the wheat-based instant cereal will improve iron status, including hemoglobin (Hb), plasma ferritin (PF) and soluble transferrin receptor (sTfR), and inflammation status, including C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP), fecal calprotectin and I-FABP; 7) the wheat-based instant cereal will decrease fecal pH, thereby providing a less favorable growth environment for enteric pathogens; 8) Maternal secretor status will affect the infant gut microbiota, with infants of secretor mothers having higher abundances of Bifidobacterium and Bacteroides but lower abundances of enteropathogens; and 9) Effects of co-provision of prebiotic mixture on the infant gut microbiota and on iron absorption, will be stronger among infants of non-secretor mothers.
This study will generate crucial data for optimizing iron and prebiotic-composition of wheat-based instant cereal designed for complementary feeding during infancy. This cereal could potentially be part of continued research on interventions to reduce the burden of IDA using safer formulations not adversely affecting the infant's gut microbiome.
- Conditions
- Iron Absorption, Gut Microbiota
- Being tested
- FeFum and 7.5 g prebiotic mixture, FeFum and 3 g prebiotic mixture, Fefum and no prebiotic mixture
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FeFum and 7.5 g prebiotic mixtureDietary supplement
The 3 weeks intervention will consist of 24 g of wheat-based instant cereal and 90 ml of water per portion and will contain 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 7.5 g prebiotics mixture
The absorption study test meals will consist of 24 g wheat-based instant cereal and 90 ml of water per portion and additionally:
Test meal 1 will be composed of: 3.6 mg of Fe as 57FeFum and 0 g prebiotic mixture added extrinsically.
Test meal 2 will be composed of: 3.6 mg of Fe as 1.5 mg iron as 58FeFum, 2.09 mg iron as 56FeFum and 7.5 g prebiotic mixture added extrinsically.
FeFum and 3 g prebiotic mixtureDietary supplement
Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 3 g prebiotics mixture per portion
Fefum and no prebiotic mixtureDietary supplement
Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) per portion.
| Study group | Role | What they receive |
|---|---|---|
| FeFum and 7.5 g prebiotic mixture | Active comparator | Intervention will be 3.6 mg Fe as Ferrous Fumarate and 7.5 g of prebiotic (high dose/low dose) mixture Receives: Dietary Supplement: FeFum and 7.5 g prebiotic mixture |
| FeFum and 3 g prebiotic mixture | Active comparator | Intervention will be 3.6 mg Fe as Ferrous Fumarate and 3 g of prebiotic (high dose/low dose) mixture Receives: Dietary Supplement: FeFum and 3 g prebiotic mixture |
| FeFum and no prebiotic mixture | Active comparator | Intervention will be 3.6 mg Fe as Ferrous Fumarate Receives: Dietary Supplement: Fefum and no prebiotic mixture |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fractional iron absorption (%)
Fractional iron absorption (erythrocyte incorporation of stable iron isotopes after 14 days of meal) from the wheat-based instant cereal containing FeFum and AA, with and without a prebiotic mixture after single dosing
Measured: Day 18
Fractional iron absorption (%)
Fractional iron absorption (erythrocyte incorporation of stable iron isotopes after 14 days of meal) from the wheat-based instant cereal containing FeFum and AA, with and without a prebiotic mixture after long-term dosing
Measured: Day 57
Secondary outcomes (12)
Change in fecal Bifidobacteria abundance
Dose-dependent prebiotic mediated-effect (7.5 g vs. 3 g vs. 0 g prebiotic) on fecal Bifidobacteria abundance before and after 3-week intervention
Measured: Day 18 and day 39
Plasma ferritin
Iron status measured at each blood draw
Measured: Baseline, Day 18, Day 39, Day 57
Soluble transferrin receptor
Iron status measured at each blood draw
Measured: Baseline, Day 18, Day 39, Day 57
C-reactive protein
Inflammation status measured at each blood draw
Measured: Baseline, Day 18, Day 39, Day 57
Alpha-1-acid glycoprotein
Inflammation status measured at each blood draw
Measured: Baseline, Day 18, Day 39, Day 57
Change in fecal calprotectin
Dose-dependent prebiotic mediated-effect (7.5 g vs. 3 g vs. 0 g prebiotic) on fecal calprotectin (inflammation marker) before and after 3-week intervention
Measured: Day 18 and Day 39
Change in intestinal integrity
An indicator of gut inflammation; assessed by measuring Intestinal fatty acid binding protein (I-FABP) in fecal samples; Dose-dependent prebiotic mediated-effect (7.5 g vs. 3 g vs. 0 g prebiotic) before and after 3-week intervention
Measured: Day 18 and day 39
Change in gut microbiome composition
Change in composition of the gut microbiome including pathogens; Dose-dependent prebiotic mediated-effect (7.5 g vs. 3 g vs. 0 g prebiotic) before and after 3-week intervention, assessed using qPCR, metagenomics and 16s sequencing
Measured: Day 18 and day 39
Change in fecal pH
Dose-dependent prebiotic mediated-effect (7.5 g vs. 3 g vs. 0 g prebiotic) before and after 3-week intervention
Measured: Day 18 and Day 39
Short chain fatty acids concentrations
Dose-dependent prebiotic mediated-effect (7.5 g vs. 3 g vs. 0 g prebiotic) before and after 3-week intervention
Measured: Day 18 and day 39
Change in viral load in nasopharynx
Potential upper respiratory tract pathogens will be assessed in the nasopharyngeal swabs collected; Dose-dependent prebiotic mediated-effect (7.5 g vs. 3 g vs. 0 g prebiotic) before and after 3-week intervention
Measured: Day 18 and day 39
Maternal secretor status and HMO concentrations
HMO concentrations in the breast milk of the mothers of the participating infants will be measured on day 39 and the maternal secretor status will be determined.
Effect of maternal secretor status on the infant gut microbiota and response to iron fortificants with or without co-provision of prebiotics will be investigated
Measured: Day 39
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Mar 2019
- Study start23 Jul 2019
- Primary completion4 Jan 2020
- Study completion4 Jan 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Iron AbsorptionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 195 participants (actual)
Sponsor and investigators
- Lead sponsor
- Swiss Federal Institute of Technology
- Sponsor type
- University, hospital or other
- Collaborators
- Danone Nutricia Research
- Responsible party
- Principal investigator, Prof. Michael B. Zimmermann, Swiss Federal Institute of Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03894358
- Sponsor's protocol ID
- INSPIRE
- Status last verified
- May 2020
- First submitted
- 7 Mar 2019
- Last updated
- 12 May 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Mikulic N, Uyoga MA, Stoffel NU, Derrien M, Nyilima S, Kostopoulos I, Roeselers G, Chenoll E, Mwasi E, Pironaci G, Karanja S, Bourdet-Sicard R, Zimmermann MB. Prebiotics increase iron absorption and reduce the adverse effects of iron on the gut microbiome and inflammation: a randomized controlled trial using iron stable isotopes in Kenyan infants. Am J Clin Nutr. 2024 Feb;119(2):456-469. doi: 10.1016/j.ajcnut.2023.11.018. Epub 2023 Nov 30.
PubMed 38042412Derrien M, Mikulic N, Uyoga MA, Chenoll E, Climent E, Howard-Varona A, Nyilima S, Stoffel NU, Karanja S, Kottler R, Stahl B, Zimmermann MB, Bourdet-Sicard R. Gut microbiome function and composition in infants from rural Kenya and association with human milk oligosaccharides. Gut Microbes. 2023 Jan-Dec;15(1):2178793. doi: 10.1080/19490976.2023.2178793.
PubMed 36794816
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Iron Absorption From a Wheat-based Instant Cereal Containing Ferrous Fumarate and Ascorbic Acid With and Without Prebiotics: Gut Microbiome and Stable Isotope Studies in Kenyan Infants
- ClinicalTrials.gov ID
- NCT03894358
- Acronym / sponsor ID
- INSPIRE
- Conditions
- Iron Absorption, Gut Microbiota
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 195 participants (actual)
- Lead sponsor
- Swiss Federal Institute of TechnologyUniversity, hospital or other
- Collaborators
- Danone Nutricia Research
- Study start
- 23 Jul 2019 (actual)
- Primary completion
- 4 Jan 2020 (actual)
- Study completion
- 4 Jan 2020 (actual)
- First posted
- 28 Mar 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to measure the effect of a prebiotic (high dose/low dose) mixture at different doses within a wheat-based instant cereal, on fractional iron absorption (FIA), gut microbiota and inflammation after three weeks. FIA will be compared with and without three weeks of pre-feeding with two different doses of the prebiotic mixture.
Detailed description
Iron deficiency anemia (IDA) is prevalent in infants and preschool children in sub-Saharan Africa. Several studies have been conducted to mitigate IDA. Some of these studies had adverse effects on the gut microbiome and diarrhea due to the high iron dose administered in areas of high burden of malaria and other common childhood infections. As a potentially safer solution, we investigated the effect of lowering the iron dose in the iron supplements and including 7.5 g galacto-oligosaccharides (GOS). Findings from these studies demonstrated that in infants, consumption of iron and GOS improved iron status, improved the gut microbiota and reduced risk of illness. We recently demonstrated that habitual consumption of GOS for three weeks resulted in improved iron absorption that correlated with a decrease in colonic pH. It is not known whether other prebiotics or a combination will also result in increased iron absorption and what the effect of using half the dose of prebiotics would be. The composition of Human Milk Oligosaccharides (HMOs) in breast milk might be an important determinant of the gut microbiome composition and health of the breastfed infant by determining the composition of Bifidobacteria species that are the main commensal 'barrier' bacteria in the infant's gut microbiome. However, little is known about the specific HMOs composition of breast milk in African populations and the potential impact on the gut microbiota composition of the breastfed infants. We therefore aim to measure the effect of a prebiotic (high dose/low dose) mixture at different doses within a wheat-based instant cereal, on fractional iron absorption (FIA) from a wheat-based instant cereal containing no prebiotic. We will compare the FIA with and without three weeks of pre-feeding with two different doses of prebiotic mixture. In addition, we will investigate the effect of two different doses of this prebiotic (high dose/low dose) mixture on gut microbiota and inflammation after three weeks.
In south coast Kenya, we will enroll 195 infants and randomize them into three intervention groups. Daily for 3 weeks, infants will consume a newly formulated wheat-based instant cereal (3.6 mg iron with Ascorbic acid (AA)) at home. Group 1 will receive the cereal with 7.5 g prebiotic mixture; group 2 will receive the cereal with 3 g prebiotic mixture and group 3 will receive the cereal with no prebiotics. In a subset of 70 infants, we will administer four labelled test meals. Two test meals will be fed 2 weeks before beginning the intervention study to investigate the acute effect of prebiotics on FIA and the other two will be fed at the end of the 3 weeks intervention study to investigate the effect of chronic consumption of prebiotics on FIA. Breast milk samples from the mothers will be collected and analyzed for the composition of human milk oligosaccharides (HMOs). We hypothesize that: 1) Infants receiving the new wheat-based instant cereal containing prebiotic (high dose/low dose) mixture will have a higher iron absorption, and 2) higher fecal Bifidobacteria abundance than infants receiving the cereal without prebiotics; 3) in infants receiving the wheat-based instant cereal, the addition of 7.5 g of prebiotic (high dose/low dose) mixture will result in higher FIA, and 4) in greater ratio of Bifidobacteria to Enterobacteriaceae, lowest fecal calprotectin, intestinal fatty acid-binding protein (I-FABP) and lowest abundances of enteropathogens than the addition of 3 g of prebiotics; 5) the addition of 7.5 g of prebiotic (high dose/low dose) mixture will result in greater FIA when administered acutely or chronically and these two effects will be additive; 6) the wheat-based instant cereal will improve iron status, including hemoglobin (Hb), plasma ferritin (PF) and soluble transferrin receptor (sTfR), and inflammation status, including C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP), fecal calprotectin and I-FABP; 7) the wheat-based instant cereal will decrease fecal pH, thereby providing a less favorable growth environment for enteric pathogens; 8) Maternal secretor status will affect the infant gut microbiota, with infants of secretor mothers having higher abundances of Bifidobacterium and Bacteroides but lower abundances of enteropathogens; and 9) Effects of co-provision of prebiotic mixture on the infant gut microbiota and on iron absorption, will be stronger among infants of non-secretor mothers.
This study will generate crucial data for optimizing iron and prebiotic-composition of wheat-based instant cereal designed for complementary feeding during infancy. This cereal could potentially be part of continued research on interventions to reduce the burden of IDA using safer formulations not adversely affecting the infant's gut microbiome.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| FeFum and 7.5 g prebiotic mixture | Active comparator | Dietary Supplement: FeFum and 7.5 g prebiotic mixtureIntervention will be 3.6 mg Fe as Ferrous Fumarate and 7.5 g of prebiotic (high dose/low dose) mixture |
| FeFum and 3 g prebiotic mixture | Active comparator | Dietary Supplement: FeFum and 3 g prebiotic mixtureIntervention will be 3.6 mg Fe as Ferrous Fumarate and 3 g of prebiotic (high dose/low dose) mixture |
| FeFum and no prebiotic mixture | Active comparator | Dietary Supplement: Fefum and no prebiotic mixtureIntervention will be 3.6 mg Fe as Ferrous Fumarate |
Who may qualify
- Ages
- 6 to 11 months
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- 6 to 11 months at baseline
- Anticipated residence in study area for the study duration
- In good health as assessed by professional staff at Msambweni County Referral hospital
- Caregiver is willing to participate and able to comply with study procedures
- Informed consent form has been read and signed by the caregiver (or has been read out to the caregiver)
Key exclusion criteria (7 listed)
- Hemoglobin concentration less than 70 g/L
- Severe underweight (Z-score weight-for-age <-3)
- Severe wasting (Z-score weight-for-height <-3
- Chronic or acute illness or other conditions that in the opinion of the Principal Investigator (PI) or study pediatrician would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol
- Participant taking part in other studies requiring the drawing of blood
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FeFum and 7.5 g prebiotic mixtureThe 3 weeks intervention will consist of 24 g of wheat-based instant cereal and 90 ml of water per portion and will contain 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 7.5 g prebiotics mixture The absorption study test meals will consist of 24 g wheat-based instant cereal and 90 ml of water per portion and additionally: Test meal 1 will be composed of: 3.6 mg of Fe as 57FeFum and 0 g prebiotic mixture added extrinsically. Test meal 2 will be composed of: 3.6 mg of Fe as 1.5 mg iron as 58FeFum, 2.09 mg iron as 56FeFum and 7.5 g prebiotic mixture added extrinsically. | Dietary supplement | FeFum and 7.5 g prebiotic mixture |
| FeFum and 3 g prebiotic mixtureStandard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 3 g prebiotics mixture per portion | Dietary supplement | FeFum and 3 g prebiotic mixture |
| Fefum and no prebiotic mixtureStandard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) per portion. | Dietary supplement | FeFum and no prebiotic mixture |
Primary outcome
Fractional iron absorption (%)
Time frame: Day 18
Fractional iron absorption (erythrocyte incorporation of stable iron isotopes after 14 days of meal) from the wheat-based instant cereal containing FeFum and AA, with and without a prebiotic mixture after single dosing
Fractional iron absorption (%)
Time frame: Day 57
Fractional iron absorption (erythrocyte incorporation of stable iron isotopes after 14 days of meal) from the wheat-based instant cereal containing FeFum and AA, with and without a prebiotic mixture after long-term dosing
12 secondary outcomes
Change in fecal Bifidobacteria abundance
Time frame: Day 18 and day 39
Plasma ferritin
Time frame: Baseline, Day 18, Day 39, Day 57
Soluble transferrin receptor
Time frame: Baseline, Day 18, Day 39, Day 57
C-reactive protein
Time frame: Baseline, Day 18, Day 39, Day 57
Alpha-1-acid glycoprotein
Time frame: Baseline, Day 18, Day 39, Day 57
Change in fecal calprotectin
Time frame: Day 18 and Day 39
Change in intestinal integrity
Time frame: Day 18 and day 39
Change in gut microbiome composition
Time frame: Day 18 and day 39
Change in fecal pH
Time frame: Day 18 and Day 39
Short chain fatty acids concentrations
Time frame: Day 18 and day 39
Change in viral load in nasopharynx
Time frame: Day 18 and day 39
Maternal secretor status and HMO concentrations
Time frame: Day 39
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2020.
- Derived from this study: PubMed 38042412Mikulic N, Uyoga MA, Stoffel NU, Derrien M, Nyilima S, Kostopoulos I, Roeselers G, Chenoll E, Mwasi E, Pironaci G, Karanja S, Bourdet-Sicard R, Zimmermann MB. Prebiotics increase iron absorption and reduce the adverse effects of iron on the gut microbiome and inflammation: a randomized controlled trial using iron stable isotopes in Kenyan infants. Am J Clin Nutr. 2024 Feb;119(2):456-469. doi: 10.1016/j.ajcnut.2023.11.018. Epub 2023 Nov 30.
- Derived from this study: PubMed 36794816Derrien M, Mikulic N, Uyoga MA, Chenoll E, Climent E, Howard-Varona A, Nyilima S, Stoffel NU, Karanja S, Kottler R, Stahl B, Zimmermann MB, Bourdet-Sicard R. Gut microbiome function and composition in infants from rural Kenya and association with human milk oligosaccharides. Gut Microbes. 2023 Jan-Dec;15(1):2178793. doi: 10.1080/19490976.2023.2178793.
- Individual participant dataSharing planned: No
Related trials for Iron Absorption
Active, not recruitingObservational study
Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption
Anemia, Iron Deficiency, Iron Overload
Active, not recruitingObservational study
Ethnic Differences in Iron Absorption (FeGenes)
Anemia, Iron Deficiency, Iron Overload
Active, not recruiting
The Effects of Acute Erythropoietin on Hepcidin and Dietary Iron Absorption Following Military-relevant Exercise in Energy Deficit: Pilot Study
Iron Absorption
RecruitingObservational study
Long-term Iron Absorption and Loss in Women
Obesity & Overweight, Normal Weight Adults
Active, not recruitingObservational study
Iron Absorption From Lipid-Based Nutrient Supplements
Undernutrition, Healthy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing FeFum and 7.5 g prebiotic mixture, FeFum and 3 g prebiotic mixture and Fefum and no prebiotic mixture in people with Iron Absorption and Gut Microbiota, run by Swiss Federal Institute of Technology at 1 site in Kenya.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 May 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Kenya. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fractional iron absorption (%) (time frame: Day 18). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03894358, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2020.